

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Zai Lab Limited**

**再鼎醫藥有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9688)**

## **CHANGE IN INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM AND AUDITOR AND ANNUAL MEETING**

Reference is made to (i) the announcement of Zai Lab Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated April 21, 2022 regarding the change of independent registered public accounting firm and auditor of the Company, (ii) the definitive proxy statement/circular for the 2022 annual general meeting of the Company dated May 3, 2022 (the “**Circular**”), and (iii) the definitive additional materials/supplemental announcement to the Circular dated May 22, 2022 in relation to the virtual 2022 annual general meeting of the Company (the “**Annual Meeting**”).

On May 25, 2022, the Company received the requisite approvals from The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and the Financial Reporting Council of Hong Kong (the “**FRC**”) for the Company’s appointment of KPMG LLP. On May 31, 2022, the Company and KPMG LLP signed an engagement letter, and the appointment became effective on the same date. KPMG LLP is an accounting firm located in the United States and is subject to full inspection and review by the Public Company Accounting Oversight Board.

Following the completion of Deloitte Touche Tohmatsu Certified Public Accountants LLP and Deloitte Touche Tohmatsu’s (together, “**Deloitte**”) services for the Group’s quarterly report on Form 10-Q for the quarter ended March 31, 2022 and the Company’s receipt of such approvals from the Hong Kong Stock Exchange and the FRC, the dismissal of Deloitte as the Company’s independent registered public accounting firm and auditor, respectively, is now effective.

During the fiscal years ended December 31, 2021 and December 31, 2020 and the subsequent interim period through the date of this announcement, there were (i) no disagreements with Deloitte in any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement(s), if not resolved to the satisfaction of Deloitte, would have caused it to make reference to the subject matter of the disagreement(s) in connection with its reports for such years and interim period, and (ii) no reportable events, as described in Item 304(a)(1)(v) of Regulation S-K. In addition, there were no other disagreements or unresolved matters between the Company and Deloitte in respect of the matters described herein that need to

be brought to the attention of the Company's shareholders and creditors, and there are no matters in respect of the dismissal of the Company's auditor that need to be brought to the attention of the shareholders of the Company. Deloitte has also provided a written confirmation that there are no matters in connection with its dismissal that need to be brought to the attention of the shareholders of the Company.

## **ANNUAL MEETING**

As previously announced, the Annual Meeting will be held on June 22, 2022 at 8:00 a.m. (U.S. Eastern Time)/8:00 p.m. (Shanghai and Hong Kong Time). Shareholders of record of the Company's ordinary shares as of the relevant record date may attend the Annual Meeting virtually by visiting the Company's Annual Meeting website at [www.virtualshareholdermeeting.com/ZLAB2022](http://www.virtualshareholdermeeting.com/ZLAB2022).

Shareholders of record of the Company's ordinary shares as of the relevant record date will be able to cast their votes on the resolutions and submit questions online during the Annual Meeting.

By order of the Board  
**Zai Lab Limited**  
**Samantha Du**  
*Director, Chairperson and  
Chief Executive Officer*

Hong Kong, June 1, 2022

*As at the date of this announcement, the board of directors of the Company comprises Dr. Samantha Du as a director, and Dr. Kai-Xian Chen, Dr. John Diekman, Ms. Nisa Leung, Mr. William Lis, Mr. Leon O. Moulder, Jr., Mr. Peter Wirth, Mr. Scott W Morrison and Richard Gaynor, MD. as independent directors.*

\* *For identification only*